Bogdan B. Guda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bogdan B. Guda has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Victor Volodymyrovich Pushkarev
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
13 shared publications - Igor I. Komisarenko
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
12 shared publications - Olena Igorevna Kovzun
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
10 shared publications - Nataliia Levchuk
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
8 shared publications - Nataliia Ya. Kobrynska
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
8 shared publications - Marian V. Оstafiychuk
ДУ «Інститут ендокринології та обміну речовин ім. В.П. Комісаренка НАМН України
7 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (7) , 755-759
Expression of acid-sensing ion channel 1 in papillary thyroid carcinoma and metastatic lesions
Background. Acid-sensing ion channel 1 (ASIC1) is a proton-gated cation channel encoded by the ASIC1 gene, one of five paralogous genes that form trimeric acid-sensing ion channels in mammals. An acidic extracellular microenvironment is a hallmark of solid tumors. ASIC1 is activated by extracellular acidification and functions as a key sensor of tumor acidosis. Increasing evidence indicates that ASIC1 contributes to multiple aspects of tumor biology, including cancer cell proliferation, migration, invasion, and metastatic dissemination. Aberrant ASIC1 expression has been reported in several malignancies, including hepatocellular, breast, gastric, brain and other cancers, suggesting that this ion channel may represent a novel biomarker and therapeutic target. The purpose was to investigate ASIC1 expression in conditionally normal thyroid tissue, primary papillary thyroid carcinoma (PTC), and metastatic lesions, and to evaluate its association with metastatic progression. Materials and methods. Postoperative samples of tissue were obtained from the surgical department of the clinic. The amount of ASIC1 was determined using enzyme immunoassay kits. Results. ASIC1 expression was significantly higher in primary PTC tissue without metastases than in adjacent conditionally normal tissue. Furthermore, tumors with lymph node metastases exhibited significantly greater ASIC1 expression than non-metastatic PTCs. The highest ASIC1 expression levels were detected in recurrent metastatic lesions, indicating a progressive increase in expression during tumor dissemination and recurrence. Conclusions. Elevated ASIC1 expression is associated with papillary thyroid carcinoma progression and metastatic potential. These findings suggest that ASIC1 may serve as a promising diagnostic biomarker for PTC and a potential predictor of metastatic spread, particularly recurrent metastasis. Further studies are warranted to clarify the mechanistic role of ASIC1 in thyroid cancer progression and to assess its value as a therapeutic target.
- 14 November 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (7) , 755-759
Open AccessExpression of acid-sensing ion channel 1 in papillary thyroid carcinoma and metastatic lesions
Background. Acid-sensing ion channel 1 (ASIC1) is a proton-gated cation channel encoded by the ASIC1 gene, one of five paralogous genes that form trimeric acid-sensing ion channels in mammals. An acidic extracellular microenvironment is a hallmark of solid tumors. ASIC1 is activated by extracellular acidification and functions as a key sensor of tumor acidosis. Increasing evidence indicates that ASIC1 contributes to multiple aspects of tumor biology, including cancer cell proliferation, migration, invasion, and metastatic dissemination. Aberrant ASIC1 expression has been reported in several malignancies, including hepatocellular, breast, gastric, brain and other cancers, suggesting that this ion channel may represent a novel biomarker and therapeutic target. The purpose was to investigate ASIC1 expression in conditionally normal thyroid tissue, primary papillary thyroid carcinoma (PTC), and metastatic lesions, and to evaluate its association with metastatic progression. Materials and methods. Postoperative samples of tissue were obtained from the surgical department of the clinic. The amount of ASIC1 was determined using enzyme immunoassay kits. Results. ASIC1 expression was significantly higher in primary PTC tissue without metastases than in adjacent conditionally normal tissue. Furthermore, tumors with lymph node metastases exhibited significantly greater ASIC1 expression than non-metastatic PTCs. The highest ASIC1 expression levels were detected in recurrent metastatic lesions, indicating a progressive increase in expression during tumor dissemination and recurrence. Conclusions. Elevated ASIC1 expression is associated with papillary thyroid carcinoma progression and metastatic potential. These findings suggest that ASIC1 may serve as a promising diagnostic biomarker for PTC and a potential predictor of metastatic spread, particularly recurrent metastasis. Further studies are warranted to clarify the mechanistic role of ASIC1 in thyroid cancer progression and to assess its value as a therapeutic target.
- Open Access
- 2 October 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (6) , 593-598
Inhibitor of nuclear factor kappa B expression in papillary thyroid carcinoma and benign neoplasms
Background. The eukaryotic transcription factor NF-κB regulates a variety of biological processes, particularly immune response and inflammatory processes. Dysregulation of NF-κB-dependent signaling mechanisms is associated with serious human diseases, including cancer, autoimmune diseases, and chronic inflammation. NF-κB inhibitor kappa B subunit beta (IκBβ) plays a key role in regulating NF-κB activity and is implicated in thyroid cancer, particularly in aggressive and metastatic forms. The aim of this study was to compare levels of IκBβ in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), and in blood plasma of PTC patients. Materials and methods. Postoperative samples of tissues, blood plasma were obtained from the surgical department of the V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU clinic. The amount of IκBβ was determined using enzyme immunoassay kits. Results. There were no significant differences between IκBβ levels in benign neoplasms and CN tissue. A minor difference was detected between CN tissue and PTC tissue without metastases. In PTC tissues with metastases, IκBβ levels were more than 1.5-fold lower than in CN tissue. The lowest IκBβ levels were detected in metastatic tissue. Рlasma IκBβ concentrations in PTC patients were significantly lower than in controls, with no differences between patients with and without metastases. Conclusions. IκBβ levels in benign thyroid neoplasms did not differ from CN tissue. In metastatic PTC tissues and especially in metastatic lesions, IκBβ concentrations were significantly reduced compared to CN tissue. Decreased IκBβ levels in primary tumors and metastatic lesions may indicate NF-κB activation and enhanced inflammatory signaling. Alterations in IκBβ expression may be useful for predicting metastatic potential in PTC, while plasma IκBβ levels could serve as a potential preoperative diagnostic biomarker.
- 2 October 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (6) , 593-598
Open AccessInhibitor of nuclear factor kappa B expression in papillary thyroid carcinoma and benign neoplasms
Background. The eukaryotic transcription factor NF-κB regulates a variety of biological processes, particularly immune response and inflammatory processes. Dysregulation of NF-κB-dependent signaling mechanisms is associated with serious human diseases, including cancer, autoimmune diseases, and chronic inflammation. NF-κB inhibitor kappa B subunit beta (IκBβ) plays a key role in regulating NF-κB activity and is implicated in thyroid cancer, particularly in aggressive and metastatic forms. The aim of this study was to compare levels of IκBβ in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), and in blood plasma of PTC patients. Materials and methods. Postoperative samples of tissues, blood plasma were obtained from the surgical department of the V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU clinic. The amount of IκBβ was determined using enzyme immunoassay kits. Results. There were no significant differences between IκBβ levels in benign neoplasms and CN tissue. A minor difference was detected between CN tissue and PTC tissue without metastases. In PTC tissues with metastases, IκBβ levels were more than 1.5-fold lower than in CN tissue. The lowest IκBβ levels were detected in metastatic tissue. Рlasma IκBβ concentrations in PTC patients were significantly lower than in controls, with no differences between patients with and without metastases. Conclusions. IκBβ levels in benign thyroid neoplasms did not differ from CN tissue. In metastatic PTC tissues and especially in metastatic lesions, IκBβ concentrations were significantly reduced compared to CN tissue. Decreased IκBβ levels in primary tumors and metastatic lesions may indicate NF-κB activation and enhanced inflammatory signaling. Alterations in IκBβ expression may be useful for predicting metastatic potential in PTC, while plasma IκBβ levels could serve as a potential preoperative diagnostic biomarker.
- Open Access
- 17 June 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (4) , 387-396
Anaplastic thyroid cancer: clinical characteristics and prognostic factors of the most lethal thyroid cancer
Background. The literature data of recent years reflect a significant increase in scientific interest in etiology, molecular abnormalities, biological features, prognostic variables, and therapeutic options for anaplastic thyroid cancer. The rarity of pathology, the difficulties in rapid diagnosis, and the lack of effective approaches to treatment lead to a catastrophically low survival rate. At the same time, a comprehensive approach to the problem (molecular pathogenesis, accurate diagnosis, clinical manifestations, improved multimodal therapy) can ensure significant progress in the treatment of carcinoma, the most aggressive of all thyroid tumors. The purpose of the work is to conduct a retrospective analysis of clinical data from patients with anaplastic thyroid cancer regarding diagnosis, tumor characteristics, and factors that may affect the duration of the postoperative period and survival rate. Materials and methods. A retrospective analysis was conducted of data from 27 patients with anaplastic thyroid cancer who were examined and operated on between 1989 and 2024. The following factors were analyzed: age, gender, tumor size, cytological findings of aspirates, presence of metastases (regional and distant) and carcinoma invasion (into the tumor capsule and vessels, intra- or extrathyroidal), extent of surgical intervention, postoperative treatment, as well as life expectancy and survival rate. Results. No differences were found in the clinical characteristics of the disease, the median duration of postoperative life, the level of mortality and survival of patients of either sex, which is significantly distinct from that in differentiated thyroid carcinomas. Clinical characteristics such as significant size of tumors, their wide invasiveness (spreading to critical organs surrounding the gland), regional metastasis mainly to the lateral cervical lymph nodes, the presence of distant metastases (their frequency increases with increasing tumor size), catastrophically low postoperative life expectancy (which is even more reduced in the presence of these characteristics), and high mortality indicate the hyperaggressive nature of anaplastic carcinoma. Intra- and extrathyroidal invasion, distant metastasis, and tumor size greater than 8 cm are prognostic biological markers of patient survival, and complete tumor resection and external beam radiation therapy are positive therapeutic factors that influence disease prognosis. Conclusions. Targeted research into the main pathogenetic and clinical aspects of pathology, as well as improving the multimodal treatment strategy, including existing methods together with the development and application of targeted and immunotherapy, can significantly improve the overall survival of doomed patients.
- 17 June 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (4) , 387-396
Open AccessAnaplastic thyroid cancer: clinical characteristics and prognostic factors of the most lethal thyroid cancer
Background. The literature data of recent years reflect a significant increase in scientific interest in etiology, molecular abnormalities, biological features, prognostic variables, and therapeutic options for anaplastic thyroid cancer. The rarity of pathology, the difficulties in rapid diagnosis, and the lack of effective approaches to treatment lead to a catastrophically low survival rate. At the same time, a comprehensive approach to the problem (molecular pathogenesis, accurate diagnosis, clinical manifestations, improved multimodal therapy) can ensure significant progress in the treatment of carcinoma, the most aggressive of all thyroid tumors. The purpose of the work is to conduct a retrospective analysis of clinical data from patients with anaplastic thyroid cancer regarding diagnosis, tumor characteristics, and factors that may affect the duration of the postoperative period and survival rate. Materials and methods. A retrospective analysis was conducted of data from 27 patients with anaplastic thyroid cancer who were examined and operated on between 1989 and 2024. The following factors were analyzed: age, gender, tumor size, cytological findings of aspirates, presence of metastases (regional and distant) and carcinoma invasion (into the tumor capsule and vessels, intra- or extrathyroidal), extent of surgical intervention, postoperative treatment, as well as life expectancy and survival rate. Results. No differences were found in the clinical characteristics of the disease, the median duration of postoperative life, the level of mortality and survival of patients of either sex, which is significantly distinct from that in differentiated thyroid carcinomas. Clinical characteristics such as significant size of tumors, their wide invasiveness (spreading to critical organs surrounding the gland), regional metastasis mainly to the lateral cervical lymph nodes, the presence of distant metastases (their frequency increases with increasing tumor size), catastrophically low postoperative life expectancy (which is even more reduced in the presence of these characteristics), and high mortality indicate the hyperaggressive nature of anaplastic carcinoma. Intra- and extrathyroidal invasion, distant metastasis, and tumor size greater than 8 cm are prognostic biological markers of patient survival, and complete tumor resection and external beam radiation therapy are positive therapeutic factors that influence disease prognosis. Conclusions. Targeted research into the main pathogenetic and clinical aspects of pathology, as well as improving the multimodal treatment strategy, including existing methods together with the development and application of targeted and immunotherapy, can significantly improve the overall survival of doomed patients.
- Open Access
- 15 June 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (2) , 7-13
LEVEL OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN MEDULLARY AND PAPILLARY THYROID CARCINOMAS
Monocyte chemoattractant protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), is a prototypical member of the C-C chemokine superfamily (MCP-1/2/3/4) that signals through G protein–coupled receptors to orchestrate leukocyte recruitment. By regulating the trafficking and activation of monocytes and basophils, MCP-1 critically modulates inflammatory responses. In the oncologic context, MCP-1 promotes tumor progression and metastatic dissemination through the recruitment of tumor-associated macrophages, thereby fostering a microenvironment conducive to cancer cell survival, migration, and invasion. This study aimed to comparatively evaluate MCP-1 levels in conditionally normal (CN) thyroid tissue, primary medullary thyroid carcinoma (MTC) tissues, and corresponding metastatic (Mts) lesions, as well as in blood plasma from patients with medullary thyroid carcinoma and papillary thyroid carcinoma (PTC) with and without metastases. Materials and methods. Postoperative thyroid tissue specimens and peripheral blood plasma were collected from patients undergoing surgical treatment. MCP-1 concentrations were quantified using enzyme-linked immunosorbent assay (ELISA). Results. MCP-1 expression was significantly elevated in primary MTC tissues without metastases compared with matched CN thyroid tissue. In metastatic MTC, tissue MCP-1 levels were increased more than threefold relative to corresponding normal tissue, with the highest expression observed in lymph node metastatic deposits. Consistently, circulating MCP-1 concentrations were significantly higher in patients with metastatic MTC than in those with non-metastatic disease. No significant difference in plasma MCP-1 concentration was found between metastatic РTC and РTC without metastases. Conclusions. MCP-1 expression is markedly upregulated in metastatic versus non-metastatic medullary thyroid carcinoma at both tissue and systemic levels. These findings implicate MCP-1 as a potential preoperative biomarker for stratifying metastatic risk in medullary thyroid carcinoma.
- 15 June 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (2) , 7-13
Open AccessLEVEL OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN MEDULLARY AND PAPILLARY THYROID CARCINOMAS
Monocyte chemoattractant protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), is a prototypical member of the C-C chemokine superfamily (MCP-1/2/3/4) that signals through G protein–coupled receptors to orchestrate leukocyte recruitment. By regulating the trafficking and activation of monocytes and basophils, MCP-1 critically modulates inflammatory responses. In the oncologic context, MCP-1 promotes tumor progression and metastatic dissemination through the recruitment of tumor-associated macrophages, thereby fostering a microenvironment conducive to cancer cell survival, migration, and invasion. This study aimed to comparatively evaluate MCP-1 levels in conditionally normal (CN) thyroid tissue, primary medullary thyroid carcinoma (MTC) tissues, and corresponding metastatic (Mts) lesions, as well as in blood plasma from patients with medullary thyroid carcinoma and papillary thyroid carcinoma (PTC) with and without metastases. Materials and methods. Postoperative thyroid tissue specimens and peripheral blood plasma were collected from patients undergoing surgical treatment. MCP-1 concentrations were quantified using enzyme-linked immunosorbent assay (ELISA). Results. MCP-1 expression was significantly elevated in primary MTC tissues without metastases compared with matched CN thyroid tissue. In metastatic MTC, tissue MCP-1 levels were increased more than threefold relative to corresponding normal tissue, with the highest expression observed in lymph node metastatic deposits. Consistently, circulating MCP-1 concentrations were significantly higher in patients with metastatic MTC than in those with non-metastatic disease. No significant difference in plasma MCP-1 concentration was found between metastatic РTC and РTC without metastases. Conclusions. MCP-1 expression is markedly upregulated in metastatic versus non-metastatic medullary thyroid carcinoma at both tissue and systemic levels. These findings implicate MCP-1 as a potential preoperative biomarker for stratifying metastatic risk in medullary thyroid carcinoma.
- Open Access
- 13 May 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (3) , 241-246
The role of vascular endothelial growth factor C in thyroid cancer metastasis
Background. The vascular endothelial growth factor (VEGF) system includes several ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D and their receptors: VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-A primarily signals through VEGFR-2, promoting endothelial cell proliferation, migration, and survival. VEGF-C and VEGF-D are particularly important for lymphangiogenesis via VEGFR-3, which is highly relevant to lymph node metastasis in thyroid cancer. The aim of this study was to compare levels of VEGF in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), as well as in blood plasma and peripheral blood mononuclear cells (PBMC) of patients with PTC. Materials and methods. Postoperative samples of tissue, blood plasma, and cells were obtained from the surgical department of the IEM clinic. The amount of VEGF was determined using enzyme immunoassay kits. Results. VEGF levels in benign neoplasms did not differ from those in CN tissue. There was significant difference between CN tissue and РТС tissues without Mts. The level of VEGF-C in the РТС tissues with Mts was ~ 2.5 times higher than in CN tissues. The high level of VEGF-C was observed in the Mts tissue. The VEGF-C concentration in PTC tissue with Mts exceeded its level in the PTC tissues without Mts by more than 2 times. In plasma and, especially, PBMC of PTC patients, VEGF-C concentration significantly exceeded control levels but there were no differences between specimens with and without Mts. Conclusions. VEGF-C levels in benign thyroid neoplasms did not differ from those in CN tissue. In PTC tissues with Mts, VEGF-C concentrations were significantly elevated compared to CN and PTC tissues without Mts. Our findings reveal significant differences in VEGF concentrations between PTC tissues with and without Mts, which may be useful for predicting metastatic potential of tumor. The level of VEGF-C in plasma and PBMC can become the basis for PTC diagnosis in the preoperative period.
- 13 May 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (3) , 241-246
Open AccessThe role of vascular endothelial growth factor C in thyroid cancer metastasis
Background. The vascular endothelial growth factor (VEGF) system includes several ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D and their receptors: VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-A primarily signals through VEGFR-2, promoting endothelial cell proliferation, migration, and survival. VEGF-C and VEGF-D are particularly important for lymphangiogenesis via VEGFR-3, which is highly relevant to lymph node metastasis in thyroid cancer. The aim of this study was to compare levels of VEGF in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), as well as in blood plasma and peripheral blood mononuclear cells (PBMC) of patients with PTC. Materials and methods. Postoperative samples of tissue, blood plasma, and cells were obtained from the surgical department of the IEM clinic. The amount of VEGF was determined using enzyme immunoassay kits. Results. VEGF levels in benign neoplasms did not differ from those in CN tissue. There was significant difference between CN tissue and РТС tissues without Mts. The level of VEGF-C in the РТС tissues with Mts was ~ 2.5 times higher than in CN tissues. The high level of VEGF-C was observed in the Mts tissue. The VEGF-C concentration in PTC tissue with Mts exceeded its level in the PTC tissues without Mts by more than 2 times. In plasma and, especially, PBMC of PTC patients, VEGF-C concentration significantly exceeded control levels but there were no differences between specimens with and without Mts. Conclusions. VEGF-C levels in benign thyroid neoplasms did not differ from those in CN tissue. In PTC tissues with Mts, VEGF-C concentrations were significantly elevated compared to CN and PTC tissues without Mts. Our findings reveal significant differences in VEGF concentrations between PTC tissues with and without Mts, which may be useful for predicting metastatic potential of tumor. The level of VEGF-C in plasma and PBMC can become the basis for PTC diagnosis in the preoperative period.
- Open Access
- 27 March 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 111-118
Clinical and prognostic characteristics of poorly differentiated thyroid carcinomas
Background. Poorly differentiated thyroid cancer (РDTC) is a rare, invasive, highly malignant carcinoma originating from follicular cells that histologically has a solid, trabecular, and insular growth pattern (or their combinations). At the beginning of the 21st century, poorly differentiated carcinoma was recognized as a separate entity and histological criteria for its diagnosis were established. Despite efforts to study poorly differentiated carcinomas, they still pose a significant challenge to clinicians due to the difficulties associated with the diagnosis, urgent need for complex thyroidectomy, high recurrence rate, and significant lethality from non-anaplastic thyroid cancer. The purpose of the study: a retrospective analysis of clinical data of patients with РDTC regarding preoperative diagnosis, tumor characteristics, effectiveness of treatment strategies, factors that may affect the duration of the postoperative period and survival rate. Materials and methods. A retrospective analysis of data from 23 patients with PDTC who were examined and operated over a 20-year period was conducted. We analyzed the age, gender of the patients, tumor size and classification according to the TNM system, results of cytological studies of aspirates (fine needle aspiration biopsy), presence of invasion (into the capsule, blood and/or lymphatic vessels of the tumor, intra- or extrathyroidal), extent of surgical intervention, postoperative treatment, health status (patients in remission, prolongatio morbi, died), duration of postoperative life and cumulative survival. Results. The age of most patients with PDTC was over 50 years; the ratio of women to men was equal. There is no gender difference in the main clinical characteristics of the disease, except for larger tumor size in male patients and a higher risk of invasive carcinomas in them. Analysis of the results of cytological studies of aspirates showed their low diagnostic value in cases of PDTC: carcinoma was not correctly diagnosed in any case, and 38 % of tumors were classified as Bethesda II–IV. 87 % of patients had T3-T4 carcinomas, 78 % exceeded 4 cm in size, more than half of them were widely invasive; among metastatic tumors, 75 % had metastases to the lateral cervical lymph nodes, and cases of compression of structures surrounding the thyroid were also observed. Such unfavorable clinicopathological characteristics caused high mortality (60.9 %), short lifetime after surgery (from 5 to 84 months, average of 17.7 months) and low survival rate during the first 5 postoperative years (22.5 %). It was noted that most deaths occurred in the first 3 postoperative years, with the number/percentage of deaths decreasing with time after carcinoma removal. Conclusions. The diagnostic value of fine needle aspiration biopsy results in the preoperative diagnosis of PDTC is low. The data obtained allow us to recommend mandatory surgery in patients aged 60+ with a Bethesda III–IV diagnosis. Tumor invasion within the thyroid gland, presence of metastases in cervical lymph nodes, and absence of postoperative radiation therapy may be risk factors for death in the first years after surgery, while patient age, tumor size, and extrathyroidal invasion are the main prognostic biological markers of survival in patients with poorly differentiated thyroid cancer.
- 27 March 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 111-118
Open AccessClinical and prognostic characteristics of poorly differentiated thyroid carcinomas
Background. Poorly differentiated thyroid cancer (РDTC) is a rare, invasive, highly malignant carcinoma originating from follicular cells that histologically has a solid, trabecular, and insular growth pattern (or their combinations). At the beginning of the 21st century, poorly differentiated carcinoma was recognized as a separate entity and histological criteria for its diagnosis were established. Despite efforts to study poorly differentiated carcinomas, they still pose a significant challenge to clinicians due to the difficulties associated with the diagnosis, urgent need for complex thyroidectomy, high recurrence rate, and significant lethality from non-anaplastic thyroid cancer. The purpose of the study: a retrospective analysis of clinical data of patients with РDTC regarding preoperative diagnosis, tumor characteristics, effectiveness of treatment strategies, factors that may affect the duration of the postoperative period and survival rate. Materials and methods. A retrospective analysis of data from 23 patients with PDTC who were examined and operated over a 20-year period was conducted. We analyzed the age, gender of the patients, tumor size and classification according to the TNM system, results of cytological studies of aspirates (fine needle aspiration biopsy), presence of invasion (into the capsule, blood and/or lymphatic vessels of the tumor, intra- or extrathyroidal), extent of surgical intervention, postoperative treatment, health status (patients in remission, prolongatio morbi, died), duration of postoperative life and cumulative survival. Results. The age of most patients with PDTC was over 50 years; the ratio of women to men was equal. There is no gender difference in the main clinical characteristics of the disease, except for larger tumor size in male patients and a higher risk of invasive carcinomas in them. Analysis of the results of cytological studies of aspirates showed their low diagnostic value in cases of PDTC: carcinoma was not correctly diagnosed in any case, and 38 % of tumors were classified as Bethesda II–IV. 87 % of patients had T3-T4 carcinomas, 78 % exceeded 4 cm in size, more than half of them were widely invasive; among metastatic tumors, 75 % had metastases to the lateral cervical lymph nodes, and cases of compression of structures surrounding the thyroid were also observed. Such unfavorable clinicopathological characteristics caused high mortality (60.9 %), short lifetime after surgery (from 5 to 84 months, average of 17.7 months) and low survival rate during the first 5 postoperative years (22.5 %). It was noted that most deaths occurred in the first 3 postoperative years, with the number/percentage of deaths decreasing with time after carcinoma removal. Conclusions. The diagnostic value of fine needle aspiration biopsy results in the preoperative diagnosis of PDTC is low. The data obtained allow us to recommend mandatory surgery in patients aged 60+ with a Bethesda III–IV diagnosis. Tumor invasion within the thyroid gland, presence of metastases in cervical lymph nodes, and absence of postoperative radiation therapy may be risk factors for death in the first years after surgery, while patient age, tumor size, and extrathyroidal invasion are the main prognostic biological markers of survival in patients with poorly differentiated thyroid cancer.
- Open Access
- 27 March 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 135-139
Fibroblast growth factor 19 level in blood plasma, thyroid tumors and metastasis
Background. The endocrine subfamily of fibroblast growth factor 19 (FGF19) consists of FGF19, FGF21, and FGF23. Numerous data indicate that FGF19 is involved in carcinogenesis, epithelial-mesenchymal transition, metastasis formation, and tumor resistance to inhibitors. The purpose of the study was to compare the levels of FGF19 in tissue samples of follicular adenoma, goiter, papillary thyroid carcinoma (PTC), metastasis (Mts), and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma, obtained from the surgical department of the IEM clinic, were used for research. The amount of FGF19 was determined using enzyme immunoassay kits. Results. The level of FGF19 in the tissue of follicular adenoma and goiter exceeded the levels in conditionally normal tissue. There was also significant difference between normal tissue and РТС tissues with and without Mts. It is important to note that the level of FGF19 in metastasis was higher than in the tumor tissue of the РТС. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 significantly exceeded its level in control plasma and in the blood of patients with PTC without Mts. In plasma of patients with PTC without Mts, the concentration of the FGF19 did not differ from its concentration in blood of healthy people. Conclusions. Our data indicate significant differences in the concentration of FGF19 between tumor tissues of PTC and Mts. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 exceeded its level in control plasma and the concentration of FGF19 in the blood of patients with PTC without Mts. There was no difference between level of FGF19 in the blood of patients with PTC without Mts and in control plasma. The latter facts may be useful for predicting the formation of Mts.
- 27 March 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 135-139
Open AccessFibroblast growth factor 19 level in blood plasma, thyroid tumors and metastasis
Background. The endocrine subfamily of fibroblast growth factor 19 (FGF19) consists of FGF19, FGF21, and FGF23. Numerous data indicate that FGF19 is involved in carcinogenesis, epithelial-mesenchymal transition, metastasis formation, and tumor resistance to inhibitors. The purpose of the study was to compare the levels of FGF19 in tissue samples of follicular adenoma, goiter, papillary thyroid carcinoma (PTC), metastasis (Mts), and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma, obtained from the surgical department of the IEM clinic, were used for research. The amount of FGF19 was determined using enzyme immunoassay kits. Results. The level of FGF19 in the tissue of follicular adenoma and goiter exceeded the levels in conditionally normal tissue. There was also significant difference between normal tissue and РТС tissues with and without Mts. It is important to note that the level of FGF19 in metastasis was higher than in the tumor tissue of the РТС. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 significantly exceeded its level in control plasma and in the blood of patients with PTC without Mts. In plasma of patients with PTC without Mts, the concentration of the FGF19 did not differ from its concentration in blood of healthy people. Conclusions. Our data indicate significant differences in the concentration of FGF19 between tumor tissues of PTC and Mts. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 exceeded its level in control plasma and the concentration of FGF19 in the blood of patients with PTC without Mts. There was no difference between level of FGF19 in the blood of patients with PTC without Mts and in control plasma. The latter facts may be useful for predicting the formation of Mts.
- Open Access
- 15 March 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (1) , 7-13
DETERMINATION OF SURVIVIN AND PROTEIN KINASE AKT IN PAPILLARY THYROID CARCINOMA AND METASTASIS TISSUES
Background. Survivin is a member of Inhibitors of Apoptosis proteins (IAP) family. It is expressed in actively proliferating cells, and is upregulated in most cancers; consequently, it has received significant attention as a potential oncotherapeutic target. Akt is a central signalling molecule of the phosphoinositide 3-kinase (PI3K)/Akt signalling pathway. It is a serine/threonine-specific protein kinase and involved in apoptosis, proliferation, transcription and migration. Aberrant activation of this pathway has been identified in a wide range of cancers and thyroid as well. The aim of the study was to compare the expression of survivin and activation of protein kinase Akt in the tissues of patients with goiter, multinodular goiter (MNG), papillary thyroid carcinoma (PTC) with and without metastasis (Mts) to the lymph nodes. Materials and methods. Postoperative specimens of tumor tissue, metastasis (Mts), benign neoplasms (goiters) and conditionally normal tissue were used for the studies. The expression of survivin mRNA was determined using real-time polymerase chain reaction (qPCR). The expression of Akt was determined using Western-blotting. Results. The obtained data indicate that the expression of the survivin mRNA in PTC tissue and Mts significantly exceeds the level of its expression in conditionally normal (more than 4.5 times) and goiter tissues. The expression of survivin in PTC without metastasis more than three times lower compared to PTC with metastasis. In metastasis the level of IAP mRNA expression is lower than in the primary tumor. The expression of the phosphorylated (activated) form of Akt in PTC tissue and Mts significantly higher than level of its expression in conditionally normal tissue. The level of Akt in Mts is almost 4 times higher than in the primary tumor and almost 8 times higher than in the conditionally normal tissue. Сonclusions. Thus, an increased survivin mRNA expression in papillary thyroid carcinoma may be marker of metastasis formation. It can also be used to differentiate between benign and malignant thyroid lesions. The level of the phosphorylated (activated) form of Akt is especially high in metastasis.
- 15 March 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (1) , 7-13
Open AccessDETERMINATION OF SURVIVIN AND PROTEIN KINASE AKT IN PAPILLARY THYROID CARCINOMA AND METASTASIS TISSUES
Background. Survivin is a member of Inhibitors of Apoptosis proteins (IAP) family. It is expressed in actively proliferating cells, and is upregulated in most cancers; consequently, it has received significant attention as a potential oncotherapeutic target. Akt is a central signalling molecule of the phosphoinositide 3-kinase (PI3K)/Akt signalling pathway. It is a serine/threonine-specific protein kinase and involved in apoptosis, proliferation, transcription and migration. Aberrant activation of this pathway has been identified in a wide range of cancers and thyroid as well. The aim of the study was to compare the expression of survivin and activation of protein kinase Akt in the tissues of patients with goiter, multinodular goiter (MNG), papillary thyroid carcinoma (PTC) with and without metastasis (Mts) to the lymph nodes. Materials and methods. Postoperative specimens of tumor tissue, metastasis (Mts), benign neoplasms (goiters) and conditionally normal tissue were used for the studies. The expression of survivin mRNA was determined using real-time polymerase chain reaction (qPCR). The expression of Akt was determined using Western-blotting. Results. The obtained data indicate that the expression of the survivin mRNA in PTC tissue and Mts significantly exceeds the level of its expression in conditionally normal (more than 4.5 times) and goiter tissues. The expression of survivin in PTC without metastasis more than three times lower compared to PTC with metastasis. In metastasis the level of IAP mRNA expression is lower than in the primary tumor. The expression of the phosphorylated (activated) form of Akt in PTC tissue and Mts significantly higher than level of its expression in conditionally normal tissue. The level of Akt in Mts is almost 4 times higher than in the primary tumor and almost 8 times higher than in the conditionally normal tissue. Сonclusions. Thus, an increased survivin mRNA expression in papillary thyroid carcinoma may be marker of metastasis formation. It can also be used to differentiate between benign and malignant thyroid lesions. The level of the phosphorylated (activated) form of Akt is especially high in metastasis.
- Open Access
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 807-811
Selection of effective concentrations of paclitaxel drugs for the treatment of anaplastic thyroid cancer
Background. Anaplastic thyroid cancer (ATС) is one of the most aggressive forms of human cancer and has an extremely poor prognosis. In most cases, the tumor is inoperable. ATС, even in the absence of metastases, is considered as a stage IV systemic disease at the time of diagnosis. The recommended therapy includes intervention with the aim of maximum possible resection of the tumor (cytoreductive surgery). Since the surgical method cannot be radical, adjuvant therapy is always necessary in the form of subsequent targeted therapy, radiotherapy, etc. An urgent task facing scientists is the development and implementation of new therapeutic approaches that could significantly improve the situation with the treatment of ATC. Among the drugs used for its treatment, taxanes were noted for their highest effectiveness. The use of taxanes is limited due to their high toxicity. Therefore, research is relevant that would make it possible to choose the minimum concentrations of drugs that are still effective. The purpose of the work was to determine the minimum effective concentrations of paclitaxel (Ptx) regarding the survival of several ATC lines with different sensitivity to this drug. Materials and methods. The work used anaplastic thyroid cancer cells: KTC-2, ARO, FRO. They were cultured in RPMI-1640 medium containing 5% bovine serum, penicillin/streptomycin (100 U/ml/100 μg/ml), in an atmosphere with 5% CO2 at 37 °C. To determine the viability of anaplastic cancer cells, a WST test was performed. Results. The concentration sufficient for effective destruction of ATC cells in culture is 10 nM. Further increase in the amount of the drug up to 10,000 nM no longer affects the number of dead cells. Conclusions. The studied anaplastic thyroid cancer lines are sensitive to Ptx, with varying degrees of sensitivity. Effective cytotoxic concentrations of Ptx start at 10 nM. Further increase in drug concentration does not lead to increased tumor cell death. For the death of the entire tumor cell population, incubation with Ptx must last more than 72 hours.
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 807-811
Open AccessSelection of effective concentrations of paclitaxel drugs for the treatment of anaplastic thyroid cancer
Background. Anaplastic thyroid cancer (ATС) is one of the most aggressive forms of human cancer and has an extremely poor prognosis. In most cases, the tumor is inoperable. ATС, even in the absence of metastases, is considered as a stage IV systemic disease at the time of diagnosis. The recommended therapy includes intervention with the aim of maximum possible resection of the tumor (cytoreductive surgery). Since the surgical method cannot be radical, adjuvant therapy is always necessary in the form of subsequent targeted therapy, radiotherapy, etc. An urgent task facing scientists is the development and implementation of new therapeutic approaches that could significantly improve the situation with the treatment of ATC. Among the drugs used for its treatment, taxanes were noted for their highest effectiveness. The use of taxanes is limited due to their high toxicity. Therefore, research is relevant that would make it possible to choose the minimum concentrations of drugs that are still effective. The purpose of the work was to determine the minimum effective concentrations of paclitaxel (Ptx) regarding the survival of several ATC lines with different sensitivity to this drug. Materials and methods. The work used anaplastic thyroid cancer cells: KTC-2, ARO, FRO. They were cultured in RPMI-1640 medium containing 5% bovine serum, penicillin/streptomycin (100 U/ml/100 μg/ml), in an atmosphere with 5% CO2 at 37 °C. To determine the viability of anaplastic cancer cells, a WST test was performed. Results. The concentration sufficient for effective destruction of ATC cells in culture is 10 nM. Further increase in the amount of the drug up to 10,000 nM no longer affects the number of dead cells. Conclusions. The studied anaplastic thyroid cancer lines are sensitive to Ptx, with varying degrees of sensitivity. Effective cytotoxic concentrations of Ptx start at 10 nM. Further increase in drug concentration does not lead to increased tumor cell death. For the death of the entire tumor cell population, incubation with Ptx must last more than 72 hours.
- Open Access
- 15 December 2025
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 82 (4) , 14-18
HYPOXIA-INDUCIBLE FACTOR-1α LEVEL IN BLOOD PLASMA, THYROID TUMORS AND METASTASES
Metastases are the leading cause of death from malignant tumors. Hypoxia is a hallmark of all solid tumors and their metastases, including papillary thyroid carcinoma (PTC). This leads to activation of the hypoxia-inducible factor (HIF) family of transcription factors, which modulate gene expression within both tumor cells and immune cells within the tumor microenvironment, influencing tumor progression and treatment response. The aim of the study was to compare the levels of HIF-1α in blood and tissue samples of follicular adenoma, goiter, papillary thyroid carcinoma, metastases, and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma, obtained from the surgical department of the Institute's clinic, were used for research. Patients with РТС, PTC + metastases, follicular adenoma and goiters (88 samples in total) participated in the study. Plasma from 5 individuals without thyroid disease and other chronic diseases, representative for age, was used as a control. The amount of HIF-1α was determined using enzyme immunoassay kits. Student's t-test was used to compare data groups. Values of P < 0.05 were considered significant. Results. The level of HIF-1α in the tissue of nodular goiter exceeded the levels in conditionally normal tissue by 2 times. A more then 2.5 ratio was observed in РТС tissues without metastases. The concentration of HIF-1α in the tumor tissue of the РТС with metastases was higher than in the conditionally normal tissue by more then 3.5 times. The level of HIF-1α in metastases was much lower comparing tumor tissue. In blood plasma of patients with PTC and metastases the concentration of the HIF-1α was more then 3 times higher than in control (healthy people) and more then 2 times higher than in tumor tissue of РТС without metastases. Conclusions. Our data indicate significant differences in the concentration of HIF-1α between tumor tissues of papillary thyroid carcinoma with and without metastasis. It should be emphasized the fact that in the blood plasma the level of HIF-1α was also significantly higher in papillary thyroid carcinoma patients with metastasis than in healthy people and papillary thyroid carcinoma patients without metastases. The latter circumstance can become the basis for the preoperative prognosis of the development of metastases in papillary thyroid carcinoma.
- 15 December 2025
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 82 (4) , 14-18
Open AccessHYPOXIA-INDUCIBLE FACTOR-1α LEVEL IN BLOOD PLASMA, THYROID TUMORS AND METASTASES
Metastases are the leading cause of death from malignant tumors. Hypoxia is a hallmark of all solid tumors and their metastases, including papillary thyroid carcinoma (PTC). This leads to activation of the hypoxia-inducible factor (HIF) family of transcription factors, which modulate gene expression within both tumor cells and immune cells within the tumor microenvironment, influencing tumor progression and treatment response. The aim of the study was to compare the levels of HIF-1α in blood and tissue samples of follicular adenoma, goiter, papillary thyroid carcinoma, metastases, and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma, obtained from the surgical department of the Institute's clinic, were used for research. Patients with РТС, PTC + metastases, follicular adenoma and goiters (88 samples in total) participated in the study. Plasma from 5 individuals without thyroid disease and other chronic diseases, representative for age, was used as a control. The amount of HIF-1α was determined using enzyme immunoassay kits. Student's t-test was used to compare data groups. Values of P < 0.05 were considered significant. Results. The level of HIF-1α in the tissue of nodular goiter exceeded the levels in conditionally normal tissue by 2 times. A more then 2.5 ratio was observed in РТС tissues without metastases. The concentration of HIF-1α in the tumor tissue of the РТС with metastases was higher than in the conditionally normal tissue by more then 3.5 times. The level of HIF-1α in metastases was much lower comparing tumor tissue. In blood plasma of patients with PTC and metastases the concentration of the HIF-1α was more then 3 times higher than in control (healthy people) and more then 2 times higher than in tumor tissue of РТС without metastases. Conclusions. Our data indicate significant differences in the concentration of HIF-1α between tumor tissues of papillary thyroid carcinoma with and without metastasis. It should be emphasized the fact that in the blood plasma the level of HIF-1α was also significantly higher in papillary thyroid carcinoma patients with metastasis than in healthy people and papillary thyroid carcinoma patients without metastases. The latter circumstance can become the basis for the preoperative prognosis of the development of metastases in papillary thyroid carcinoma.